Aspiro Therapeutics is on a mission to revolutionize treatment for obstructive lung diseases by mimicking the protective power of CC16, a natural lung protein vital for healthy breathing. We are focused on developing advanced, disease-modifying therapies that target the underlying mechanisms of conditions like asthma and COPD, going beyond symptom relief to alter the natural course of these diseases.
By harnessing the protective properties of CC16, we aim to restore lung function and prevent disease progression, offering patients safer and more effective treatment options. Through innovation and a commitment to improving respiratory care, we strive to make a lasting impact on the lives of those affected by obstructive lung diseases.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Tucson, Az, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.aspirotx.com
- Keywords
- Asthma, COPD, Respiratory Therapeutics, CC16, Peptide.
- HQ
- Tucson, AZ
Aspiro Therapeutics Questions
Aspiro Therapeutics's website is http://www.aspirotx.com
Aspiro Therapeutics's LinkedIn profile is https://www.linkedin.com/company/aspirotherapeutics
Aspiro Therapeutics has
4 employees.
View email and phone details for 4
employees at Aspiro Therapeutics.
Aspiro Therapeutics's industry is
Biotechnology Research
Aspiro Therapeutics's top competitors are
Harmonic Discovery,
Biosuperior Technology, Inc.,
Raesedo Inc,
Paxauris,
Maxcyte, Inc.,
U-Ploid Biotechnologies,
Stratum Biosciences,
Aces Diagnostics,
Hypersound Medical,
Macula Vision Systems.
Aspiro Therapeutics's categories are Biotechnology Research
Aspiro Therapeutics's founding year is 2024
